Search Results | Cancer Research | American Association for Cancer Research

1-20 of 57

2 3

Sort by

Sort Order Select

Journal Articles

Abstract 2275: Transcription factor landscape cataloguing highlights key insights in inflammatory breast cancer (IBC)

Diego A. Rosado-Tristani, Carlos S. Morales, Esther A. Peterson, Jose A. Rodríguez-Martínez

Cancer Res (2022) 82 (12_Supplement): 2275.

DOI: https://doi.org/10.1158/1538-7445.AM2022-2275

Published: 15 June 2022

View article

Journal Articles

Abstract 6200: MANGO: pipeline for identifying genomic translocations with key biological significance in inflammatory breast cancer

Carlos S. Morales-Rivera, Emilia R. Driscoll, Esther A. Peterson-Peguero

Cancer Res (2022) 82 (12_Supplement): 6200.

DOI: https://doi.org/10.1158/1538-7445.AM2022-6200

Published: 15 June 2022

View article

Journal Articles

Abstract 329: Understanding the role of GPR30 in the estrogen non-genomic signaling in inflammatory breast cancer

Xavier S. Bittman Soto, Adrian J. Rivera Lopez, Esther A. Peterson

Cancer Res (2022) 82 (12_Supplement): 329.

DOI: https://doi.org/10.1158/1538-7445.AM2022-329

Published: 15 June 2022

View article

Journal Articles

Abstract LB-330: Phase I study of procaspase activating compound-1 (PAC-1) for treatment of advanced malignancies

Oana C. Danciu, Matthias Holdhoff, Richard A. Peterson, Paul J. Hergenrother, Theodore M. Tarasow, Arkadiusz Z. Dudek

Cancer Res (2020) 80 (16_Supplement): LB-330.

DOI: https://doi.org/10.1158/1538-7445.AM2020-LB-330

Published: 15 August 2020

View article

Journal Articles

Abstract CT027: Phase I study of procaspase activating compound -1 (PAC-1) in the treatment of advanced malignancies and in combination with temozolomide in refractory high-grade astrocytomas

Oana C. Danciu, M. Kelly Nicholas, Matthias Holdhoff, Richard A. Peterson, Neeta Venepalli, Rozina Chowdhery, Paul J. Hergenrother, Theodore M. Tarasow, Arkadiusz Z. Dudek

Cancer Res (2019) 79 (13_Supplement): CT027.

DOI: https://doi.org/10.1158/1538-7445.AM2019-CT027

Published: 01 July 2019

View article

Journal Articles

Abstract 3445: Functional interaction between SEPT9_v1 and EGFR in triple-negative and inflammatory breast cancer

Amanda Agosto, Jose G. Cirino, Kimberleve Rolón, Gabriel E. Figueroa, Gabriela Martinez, Katixa Montañez-Negrón, Keishla Rodríguez-Mártir, Xavier Bittman, Esther A. Peterson

Cancer Res (2018) 78 (13_Supplement): 3445.

DOI: https://doi.org/10.1158/1538-7445.AM2018-3445

Published: 01 July 2018

View article

Journal Articles

Abstract 2522: Luminal epithelial cell expression of amphiregulin is required for mammary gland development and facilitates mutant p53-driven tumorigenesis

Kristopher A. Lofgren, David R. Meier, Megan A. Girtman, Esther A. Peterson, E. Charles Jenkins, Paraic A. Kenny

Cancer Res (2018) 78 (13_Supplement): 2522.

DOI: https://doi.org/10.1158/1538-7445.AM2018-2522

Published: 01 July 2018

View article

Journal Articles

Abstract OT2-01-13: A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA)

J Litton, J Ettl, SA Hurvitz, LA Mina, HS Rugo, K-H Lee, R Yerushalmi, N Woodward, A Goncalves, F Moreno, H Roche, Y-H Im, M Martin, S Bhattacharya, A Peterson, A Hannah, W Eiermann, J Blum

Cancer Res (2017) 77 (4_Supplement): OT2-01-13.

DOI: https://doi.org/10.1158/1538-7445.SABCS16-OT2-01-13

Published: 15 February 2017

View article

Journal Articles

Abstract OT3-02-02: ENDEAR: A randomized international phase 3 study comparing the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy vs placebo with paclitaxel in patients with advanced diagnostic-positive triple-negative breast cancer

R Dent, P Schmid, J Cortes, S-B Kim, F Andre, V Abramson, F Cardoso, M Colleoni, P Morris, J Steinberg, IC Tudor, H Uppal, VE Paton, A Peterson, TA Traina

Cancer Res (2017) 77 (4_Supplement): OT3-02-02.

DOI: https://doi.org/10.1158/1538-7445.SABCS16-OT3-02-02

Published: 15 February 2017

View article

Journal Articles

Abstract P4-22-08: A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer

I Krop, J Cortes, K Miller, MT Huizing, L Provencher, L Gianni, S Chan, M Trudeau, J Steinberg, J Sugg, M Liosatos, VE Paton, A Peterson, A Wardley

Cancer Res (2017) 77 (4_Supplement): P4-22-08.

DOI: https://doi.org/10.1158/1538-7445.SABCS16-P4-22-08

Published: 15 February 2017

View article

Journal Articles

Abstract P5-06-01: Talazoparib antitumor effects in BRCA-deficient breast cancer models

VT Phan, AA Protter, A Peterson, H Uppal

Cancer Res (2017) 77 (4_Supplement): P5-06-01.

DOI: https://doi.org/10.1158/1538-7445.SABCS16-P5-06-01

Published: 15 February 2017

View article

Journal Articles

Abstract P2-08-01: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer

Cancer Res (2017) 77 (4_Supplement): P2-08-01.

DOI: https://doi.org/10.1158/1538-7445.SABCS16-P2-08-01

Published: 15 February 2017

View article

Journal Articles

Abstract P5-08-28: Incidence of germline BRCA1- and BRCA2-mutated breast cancer in the US

R Kim, A Peterson, A Isherwood, H Uppal, A Barlev

Cancer Res (2017) 77 (4_Supplement): P5-08-28.

DOI: https://doi.org/10.1158/1538-7445.SABCS16-P5-08-28

Published: 15 February 2017

View article

Journal Articles

The Proliferative Activity of Mammary Epithelial Cells in Normal Tissue Predicts Breast Cancer Risk in Premenopausal Women

Sung Jin Huh, Hannah Oh, Michael A. Peterson, Vanessa Almendro, Rong Hu, Michaela Bowden, Rosina L. Lis, Maura B. Cotter, Massimo Loda, William T. Barry, Kornelia Polyak, Rulla M. Tamimi

Cancer Res (2016) 76 (7): 1926–1934.

DOI: https://doi.org/10.1158/0008-5472.CAN-15-1927

Published: 31 March 2016

View article

Includes: Supplementary data

Journal Articles

Amphiregulin Is a Critical Downstream Effector of Estrogen Signaling in ERα-Positive Breast Cancer

Esther A. Peterson, Edmund C. Jenkins, Kristopher A. Lofgren, Natasha Chandiramani, Hui Liu, Evelyn Aranda, Maryia Barnett, Paraic A. Kenny

Cancer Res (2015) 75 (22): 4830–4838.

DOI: https://doi.org/10.1158/0008-5472.CAN-15-0709

Published: 15 November 2015

View article

Includes: Supplementary data

Journal Articles

Abstract 5046: Amphiregulin is a key effector of estrogen receptor in breast cancer

Esther A. Peterson, Natasha Chandiramani, Evelyn J. Aranda Jaque, E. Charles Jenkins, Paraic A. Kenny

Cancer Res (2015) 75 (15_Supplement): 5046.

DOI: https://doi.org/10.1158/1538-7445.AM2015-5046

Published: 01 August 2015

View article

Journal Articles

Abstract 4197: Mutant GATA3 drives precocious lobuloalveolar mammary development and promotes the growth of estrogen receptor positive xenograft tumors

Natasha Chandiramani, Esther A. Peterson, Eric H. Jung, E. Charles Jenkins, Paraic A. Kenny

Cancer Res (2015) 75 (15_Supplement): 4197.

DOI: https://doi.org/10.1158/1538-7445.AM2015-4197

Published: 01 August 2015

View article

Journal Articles

Abstract OT3-2-01: A phase 2 randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2 non-amplified advanced breast cancer

DA Yardley, A Awada, J Cortes, HA Burris, A Peterson, S Bhattacharya, L Gianni, K Miller, E Winer

Cancer Res (2013) 73 (24_Supplement): OT3-2-01.

DOI: https://doi.org/10.1158/0008-5472.SABCS13-OT3-2-01

Published: 15 December 2013

View article

Journal Articles

Abstract OT3-2-08: A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer

TA Traina, J O'Shaughnessy, C Kelly, L Schwartzberg, A Gucalp, A Peterson, S Bhattacharya, M Trudeau, CA Hudis, P Schmid

Cancer Res (2013) 73 (24_Supplement): OT3-2-08.

DOI: https://doi.org/10.1158/0008-5472.SABCS13-OT3-2-08

Published: 15 December 2013

View article

Journal Articles

Abstract 2401: Evaluation of circulating serum Amphiregulin levels in patients with breast cancer.

Esther A. Peterson, Paraic A. Kenny

Cancer Res (2013) 73 (8_Supplement): 2401.

DOI: https://doi.org/10.1158/1538-7445.AM2013-2401

Published: 15 April 2013

View article

2 3

NARROW

Abstract 2275: Transcription factor landscape cataloguing highlights key insights in inflammatory breast cancer (IBC)

Abstract 6200: MANGO: pipeline for identifying genomic translocations with key biological significance in inflammatory breast cancer

Abstract 329: Understanding the role of GPR30 in the estrogen non-genomic signaling in inflammatory breast cancer

Abstract LB-330: Phase I study of procaspase activating compound-1 (PAC-1) for treatment of advanced malignancies

Abstract CT027: Phase I study of procaspase activating compound -1 (PAC-1) in the treatment of advanced malignancies and in combination with temozolomide in refractory high-grade astrocytomas

Abstract 3445: Functional interaction between SEPT9_v1 and EGFR in triple-negative and inflammatory breast cancer

Abstract 2522: Luminal epithelial cell expression of amphiregulin is required for mammary gland development and facilitates mutant p53-driven tumorigenesis

Abstract OT2-01-13: A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA)

Abstract OT3-02-02: ENDEAR: A randomized international phase 3 study comparing the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy vs placebo with paclitaxel in patients with advanced diagnostic-positive triple-negative breast cancer

Abstract P4-22-08: A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer

Abstract P5-06-01: Talazoparib antitumor effects in BRCA-deficient breast cancer models

Abstract P2-08-01: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer

Abstract P5-08-28: Incidence of germline BRCA1- and BRCA2-mutated breast cancer in the US

The Proliferative Activity of Mammary Epithelial Cells in Normal Tissue Predicts Breast Cancer Risk in Premenopausal Women

Amphiregulin Is a Critical Downstream Effector of Estrogen Signaling in ERα-Positive Breast Cancer

Abstract 5046: Amphiregulin is a key effector of estrogen receptor in breast cancer

Abstract 4197: Mutant GATA3 drives precocious lobuloalveolar mammary development and promotes the growth of estrogen receptor positive xenograft tumors

Abstract OT3-2-01: A phase 2 randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2 non-amplified advanced breast cancer

Abstract OT3-2-08: A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer

Abstract 2401: Evaluation of circulating serum Amphiregulin levels in patients with breast cancer.

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only